NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Audio Transcript of the Earnings call for the Q3 FY2310-02-2023
10-02-2023
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publications10-02-2023
Natco Pharma's Q3 consolidated net profit dips 22% yoy at Rs 62 cr
Natco Pharma on Thursday said its consolidated net profit declined by 22 per cent to Rs 62 crore for the third quarter ended December 31, 2022. The Hyderabad-based drug firm had reported a net profit of Rs 80 crore in the October-December quarter of last fiscal. Total income of the company stood at Rs 513 crore in the period under review as compared with Rs 591 crore in the year-ago period that had a one-time licensing revenue. The company's board, which met on Thursday, approved an interim dividend of Rs 1.25 per share for the quarter ended December 31, 2022. Shares of the company ended 0.38 per cent down at Rs 529.10 apiece on the BSE.09-02-2023
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter and nine months ended 31st December, 202209-02-2023
Q3FY23 Quarterly Result Announced for Natco Pharma Ltd.
Natco Pharma announced Q3FY23 results: Consolidated Q3FY23: Total revenue of Rs 513.3 crore, for the Q3FY23, as against Rs 590.7 crore for the same period last year that had a one-time licensing revenue. The net profit for the period was Rs 62.3 crore as against Rs 80.4 crore last year. Consolidated 9MFY23: The company recorded total revenue of Rs 1,884.8 crores against Rs 1,433.2 crore for same period last year and on the net profit side, the company recorded Rs 439.5 crore as against Rs 220.5 crore. The Board of Directors has declared 3rd interim dividend of Rs 1.25 per equity share, for FY23. Result PDF09-02-2023
Q3FY23 Quarterly Result Announced for Natco Pharma Ltd.
Natco Pharma announced Q3FY23 results: Consolidated Q3FY23: Total revenue of Rs 513.3 crore, for the Q3FY23, as against Rs 590.7 crore for the same period last year that had a one-time licensing revenue. The net profit for the period was Rs 62.3 crore as against Rs 80.4 crore last year. Consolidated 9MFY23: The company recorded total revenue of Rs 1,884.8 crores against Rs 1,433.2 crore for same period last year and on the net profit side, the company recorded Rs 439.5 crore as against Rs 220.5 crore The Board of Directors has declared 3rd Interim dividend of Rs 1.25 per eqully share, for FY23. Result PDF09-02-2023
NATCO PHARMA LTD. - 524816 - Corporate Action-Board approves Dividend
Declared 3rd Interim Dividend for the Financial Year 2022-2309-02-2023
NATCO PHARMA LTD. - 524816 - Outcome Of The Board Meeting
Outcome of the Board Meeting for the un audited financial results for the quarter ended 31st December, 202209-02-2023
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate07-02-2023
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
USFDA COMPLETES INSPECTION OF NATCO's VIZAG FORMULATION FACILITY04-02-2023